Adicet Bio annual ebitda
2017
2018
2019
2020
2021
2022
2023
2024
2025
Adicet Bio EBITDA Growth & History (ACET)
Adicet Bio's calculated EBITDA was −$115.7M for fiscal 2025.
View full Adicet Bio company overviewAdicet Bio annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$115.7M | $5.4M | — |
| 2024 | 2024-12-31 | −$121.1M | $24.8M | — |
| 2023 | 2023-12-31 | −$145.9M | −$76.0M | — |
| 2022 | 2022-12-31 | −$70.0M | −$10.1M | — |
| 2021 | 2021-12-31 | −$59.9M | −$21.9M | — |
| 2020 | 2020-12-31 | −$38.0M | −$7.8M | — |
| 2019 | 2019-12-31 | −$30.1M | −$16.4M | — |
| 2018 | 2018-12-31 | −$13.7M | $5.1M | — |
| 2017 | 2017-12-31 | −$18.9M | — | — |
Adicet Bio quarterly ebitda
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$21.1M | $9.7M | — |
| Q1 2026 | 2026-03-31 | −$20.2M | $8.1M | — |
| Q4 2025 | 2025-12-31 | −$30.3M | −$1.2M | — |
| Q3 2025 | 2025-09-30 | −$26.4M | $5.2M | — |
| Q2 2025 | 2025-06-30 | −$30.8M | $457,000 | — |
| Q1 2025 | 2025-03-31 | −$28.3M | $935,000 | — |
| Q4 2024 | 2024-12-31 | −$29.1M | $695,000 | — |
| Q3 2024 | 2024-09-30 | −$31.6M | $19.1M | — |
| Q2 2024 | 2024-06-30 | −$31.2M | $2.1M | — |
| Q1 2024 | 2024-03-31 | −$29.2M | $2.8M | — |
| Q4 2023 | 2023-12-31 | −$29.8M | $722,000 | — |
| Q3 2023 | 2023-09-30 | −$50.7M | −$28.5M | — |
| Q2 2023 | 2023-06-30 | −$33.4M | −$11.1M | — |
| Q1 2023 | 2023-03-31 | −$32.1M | −$37.1M | — |
| Q4 2022 | 2022-12-31 | −$30.5M | −$15.3M | — |
| Q3 2022 | 2022-09-30 | −$22.2M | −$8.9M | — |
| Q2 2022 | 2022-06-30 | −$22.3M | −$12.0M | — |
| Q1 2022 | 2022-03-31 | $5.1M | $26.1M | — |
| Q4 2021 | 2021-12-31 | −$15.2M | −$6.2M | — |
| Q3 2021 | 2021-09-30 | −$13.3M | $45,000 | — |
| Q2 2021 | 2021-06-30 | −$10.3M | −$2.0M | — |
| Q1 2021 | 2021-03-31 | −$21.0M | −$13.8M | — |
| Q4 2020 | 2020-12-31 | −$9.0M | −$24.6M | — |
| Q3 2020 | 2020-09-30 | −$13.4M | $1.6M | — |
| Q2 2020 | 2020-06-30 | −$8.3M | $10.8M | — |
| Q1 2020 | 2020-03-31 | −$7.2M | $4.4M | — |
| Q4 2019 | 2019-12-31 | $15.6M | −$4.0M | −20.30% |
| Q3 2019 | 2019-09-30 | −$14.9M | −$5.9M | — |
| Q2 2019 | 2019-06-30 | −$19.1M | −$5.0M | — |
| Q1 2019 | 2019-03-31 | −$11.7M | −$1.5M | — |
| Q4 2018 | 2018-12-31 | $19.5M | $27.1M | — |
| Q3 2018 | 2018-09-30 | −$9.0M | −$5.1M | — |
| Q2 2018 | 2018-06-30 | −$14.1M | −$10.0M | — |
| Q1 2018 | 2018-03-31 | −$10.2M | −$6.8M | — |
| Q4 2017 | 2017-12-31 | −$7.5M | — | — |
| Q3 2017 | 2017-09-30 | −$3.9M | — | — |
| Q2 2017 | 2017-06-30 | −$4.1M | — | — |
| Q1 2017 | 2017-03-31 | −$3.4M | — | — |
Adicet Bio ebitda trends
Over the last five fiscal years, Adicet Bio's ebitda decreased from −$38.0M to −$115.7M, a change of −$77.8M. The latest reported quarter, Q2 2026, shows −$21.1M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Adicet Bio source filings ↗Community posts
Adicet reports lupus remissions and prepares pivotal study
Adicet Bio ($ACET) disclosed Phase 1 findings for its off-the-shelf CAR-T therapy prula-cel in systemic lupus erythematosus, with or without lupus nephritis. The efficacy dataset included 22 patients, with 13 followed for at least 12 months ...
